Abstract
Any chiral drug, when prepared using a chemical synthesis method, is usually obtained as a 50:50 racemic mixture of R and S enantiomers. Irrespective of whether the R or S enantiomer is the active pharmaceutical ingredient (API), a drug is more often marketed in its racemic form. Drug developers state a number of reasons for the racemate to be approved by regulatory agencies such as Investigational New Drug Application (INDA). The US Food and Drug Administration (FDA, which is the most prominent regulatory agency in the world) does not insist on a new drug being marketed as a racemic mixture or as a single enantiomer as long as its safety, efficacy and risk–benefit analyses have been thoroughly carried out by the manufacturer. In view of the huge costs involved in drug development, manufacturers use patent protection as a tool to recover the costs. In most cases, patent extension is also resorted to, but it is a serious issue involving techno-legal issues and competition from generic companies.
This is a preview of subscription content, log in via an institution to check access.
Suggested Reading
B S Reddy and P K Dubey, Chirality and drug activity, Resonance, Vol.28, pp.447–464, 2023.
A R Fassihi, Racemates and enantiomers in drug development, Int. J. Pharm., Vol.92, pp.1–14, 1993.
S Budavari (ed.), The Merck Index, 11th edn, Merck & Co., Rahway, N.J., 1989.
D Ferdinand, US Pat. No. 3261859 (To Knoll Gmbh), 1966.
D Sreeram and P Yogeeswari, Medicinal Chemistry, Dorling Kindersley (India) Pvt. Ltd., Delhi, 2008.
Indian Pharmacopoeia—2022, published by the Government of India, Ministry of Health & Family Welfare thru the Indian Pharmacopia Commission, Ghaziabad, UP.
G M Halford, M Lordkipanidze and S P Watson, 50th Anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams, Platelets, Vol.23, pp.415–432, 2012.
A C Mureson, Ibuprofen: original versus green synthesis, Ann. Dunarea Jos, Univ. Galati (Romania), Vol.3, pp.30–34, 2018. https://doi.org/10.35219/mms.2018.3.05
G Hancu and A Modroiu, Chiral switch: between therapeutic benefit and marketing strategy, Pharmaceuticals, Vol.15, pp.240–255, 2022.
Drug (Prices Control) Order, 1979. https://pharmaceuticals.gov.in>DPC01979
Hathi Committee Report, 1975.
B B Molloy and K K Schmiegel, US Pat. No. 4314081 (To Eli Lilly and Co.), 1982.
D T Wong, F P Bymaster and E A Engleman, Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication, Life Sci., Vol.57, pp.411–441, 1995.
C J Wenthur, M R Bennett and C W Lindsley, Classics in chemical neuroscience, fluoxetine (Prozac), ACS Chem. Neurosci., A-J, 2013. https://doi.org/10.1021/Cn400186j
J McConathy and M J Owens, Stereochemistry in drug action, J. Clin. Psychiatry, Vol.5, pp.70–73, 2003.
R Mehvar and D R Brocks, Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans, J. Pharm. Pharm. Sci., Vol.4, pp.185–200, 2001.
N T Phuong, B J Lee, J K Choi, J S Kang and K Kwon, Enantioselective pharmacokinetics of Carvedilol in human volunteers, Arch. Pharm, Res., Vol.27, pp.973–977, 2004.
F Wiedemann, et al., US Pat. No. 4503067 (To Boehringer Mannheim), 1985.
K S Kumar, K T Reddy, G Omprakash and P K Dubey, Synthesis and characterization of potential impurities in key intermediates of carvedilol: a adrenergic receptor, J. Chem. Pharm. Res., Vol.3, pp.33–45, 2011.
E F Domino and D S Warner, Taming the ketamine tiger, Anesthesiology, Vol.113, pp.678–684, 2010.
G Mion, History of anaesthesia: the ketamine story—past, present and future, Eur. J. Anaesthesiol., Vol.34, pp.571–575, 2017.
B S Sekhon, Exploiting the power of stereochemistry in drugs: an overview of racemic and enantiopure drugs, J. Modern Med. Chem., Vol.1, pp.10–36, 2013.
W H Brooks, W C Guida and K G Daniel, The significance of chirality in drug design and development, Curr. Top. Med. Chem., Vol.11, pp.760–770, 2011.
J A Dimasi, R W Hansen and H G Grabowski, The price of innovation: new estimates of drug development costs, J. Health Econ., Vol.22, pp.151–185, 2003.
https://en.wikipedia.org>wiki>cost_of_drug_develop
https://www.webmd.com>valsartan-oral>details
https://medlineplus.gov>druginfo>meds
P Buhlmayer, et al., US Pat. No. 5,399,578 (To Ciba Geigy), 1992.
P Buhlmayer, et al., Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series, Bioorg. Med. Chem. Lett., Vol.4, pp.29–34, 1994.
R T Morrison and R N Boyd, Organic Chemistry, Allyn and Bacon Inc., Boston, pp.151–153, 1983.
H R Black, J Bailey, D Zappe and R Samuel, Valsartan: more than a decade of experience, Drugs, Vol.69, pp.2393–2414, 2009.
https://www.medindia.net>Drugs>Drug price
V Pilla and T Thacker, Novartis heart drug price may fall by 60% on generic roll outs, The Economic Times, Hyderabad, India, dated 19 January 2023.
M Spruill and M L Cunningham, Strategies for extending the life of patents, BioPharm. Int., pp.1–4, 2005.
H Gupta, S Kumar, S K Roy and R S Gaud, Patent protection strategies, J. Pharm. Biol Sci., Vol.2, pp.2–7, 2010.
Acknowledgements
The authors are thankful to Dr P V Varaprasada Reddy and Mr D Krishnamacharyulu of NOSCH Labs Pvt. Ltd., Hyderabad, for technical help.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Pramod Kumar Dubey is a retired Professor of Chemistry from Jawaharlal Nehru Technological University, Hyderabad in 2013. His research interests are in organic and medicinal chemistry and chemical education.
Bireddy Srinivasa Reddy obtained his Ph.D. in Chemistry from Jawaharlal Nehru Technological University, Hyderabad in 2013. His research interests are in organic chemistry and chemical education.
Rights and permissions
About this article
Cite this article
Ready, B.S., Dubey, P.K. Regulatory and Patenting Aspects of Chiral Drugs. Reson 29, 557–571 (2024). https://doi.org/10.1007/s12045-024-0557-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12045-024-0557-8